Citi analyst David Lebowitz lowered the firm’s price target on Arrowhead Pharmaceuticals to $34 from $33 and keeps a Neutral rating on the shares following the fiscal Q1 report. To optimize cash burn, the company is prioritizing cardiometabolic and pulmonary verticals, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARWR:
- ARWR Upcoming Earnings Report: What to Expect?
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Arrowhead price target raised to $62 from $59 at Piper Sandler
- Arrowhead 15.8M share Secondary priced at $28.50
